For example, combinations of HDAC inhibitors with other inhibitors, such as those targeting DNA methyltransferases and BCL2, have shown promising clinical results in CTCL, although not for all patients (Rozati et al., 2016; Kim et al., 2018; Sermer et al., 2019). The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.